Note*: This report requires 5-10 business days to complete.
DelveInsight’s Neuroendocrine Carcinoma - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Crohn’s disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Neuroendocrine Carcinoma forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Neuroendocrine Carcinoma till 2023.
Key Coverage and Benefits
• The report will help in developing business strategies by understanding the trends shaping and driving the global Neuroendocrine Carcinoma market.
• Identifying patient populations in the global “Neuroendocrine Carcinomamarket to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Neuroendocrine Carcinoma therapeutics in each of the markets covered.
• To understand the future market competition in the global Neuroendocrine Carcinoma therapeutics market and Insightful review of the key market drivers and barriers.
Scope
• Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
• Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2013-2023.
• It also provides Neuroendocrine Carcinoma for United States, EU5 and Japan from 2013 and forecasted Market to 2023.
'
Table of Contents
• Neuroendocrine Carcinoma overview
• Pathophysiology
• Symptoms of disease
• Etiology of disease
• Diagnosis of disease
• Treatment of disease
• Overview of Marketed drugs
• Drug Description
• Mechanism of Action
• Pharmacokinetics Properties
• Marketed Details
• Patent Information
• Patent Exclusivity Expiry Assessment United States (US)
• Patents Details
• Historical and Forecasted sales of marketed molecules in the Global Neuroendocrine Carcinoma Market
• Global Epidemiology of Neuroendocrine Carcinoma Forecasted to 2023
• Global Market (2013-2015)
• Global Forecasted Market (2016-2023)
• Global Market by Geography
• Market of US (2013-2015)
• Forecasted Market of US (2016-2023)
• Market of Europe
• Market of Germany (2013-2015)
• Forecasted Market of Germany (2016-2023)
• Market of United Kingdom (2013-2015)
• Forecasted Market of United Kingdom (2016-2023)
• Market of France (2013-2015)
• Forecasted Market of France (2016-2023)
• Market of Italy (2013-2015)
• Forecasted Market of Italy (2016-2023)
• Market of Spain (2013-2015)
• Forecasted Market of Spain (2016-2023)
• Market of Japan (2013-2015)
• Forecasted Market of Japan (2016-2023)
• Market of ROW (2013-2015)
• Forecasted Market of ROW (2016-2023)
• Appendix
• Report Methodology
• Consulting Services
• Disclaimer
• Report Purchase Options
• About DelveInsight
List of Tables
• Table 1: Drug Description
• Table 2: Drug, Marketed Details United States (US)
• Table 3: Drug, Patent Number Specific Patent Expiry in US (Year), 2015
• Table 4: Drug, Patent Details for US
• Table 5: Neuroendocrine Carcinoma Drug Sales (USD Millions)-2023
• Table 6: Global Epidemiology of Neuroendocrine Carcinoma (2013-2023)
• Table 7: Neuroendocrine Carcinoma Global Market (USD Millions), (2013-2015)
• Table 8: Neuroendocrine Carcinoma Global Market (USD Millions), (2016-2023)
• Table 9: Neuroendocrine Carcinoma US Market (USD Millions), (2013-2015)
• Table 10: Neuroendocrine Carcinoma US Market (USD Millions), (2016-2023)
• Table 11: Neuroendocrine Carcinoma Germany Market (USD Millions), (2013-2015)
• Table 12: Neuroendocrine Carcinoma Germany Market (USD Millions), (2016-2023)
• Table 13: Neuroendocrine Carcinoma United Kingdom Market (USD Millions), (2013-2015)
• Table 14: Neuroendocrine Carcinoma United Kingdom Market (USD Millions), (2016-2023)
• Table 15: Neuroendocrine Carcinoma France Market (USD Millions), (2013-2015)
• Table 16: Neuroendocrine Carcinoma France Market (USD Millions), (2016-2023)
• Table 17: Neuroendocrine Carcinoma Italy Market (USD Millions), (2013-2015)
• Table 18: Neuroendocrine Carcinoma Italy Market (USD Millions), (2016-2023)
• Table 19: Neuroendocrine Carcinoma Spain Market (USD Millions), (2013-2015)
• Table 20: Neuroendocrine Carcinoma Spain Market (USD Millions), (2016-2023)
• Table 21: Neuroendocrine Carcinoma Japan Market (USD Millions), (2013-2015)
• Table 22: Neuroendocrine Carcinoma Japan Market (USD Millions), (2016-2023)
• Table 23: Neuroendocrine Carcinoma ROW Market (USD Millions), (2013-2015)
• Table 24: Neuroendocrine Carcinoma ROW Market (USD Millions), (2016-2023)
List of Figures
• Figure 1: Neuroendocrine Carcinoma Drug Sales (USD Millions)-2023
• Figure 2: Global Epidemiology of Neuroendocrine Carcinoma (2013-2023)
• Figure 3: Neuroendocrine Carcinoma Global Market (USD Millions), (2013-2015)
• Figure 4: Neuroendocrine Carcinoma Global Market (USD Millions), (2016-2023)
• Figure 5: Neuroendocrine Carcinoma US Market (USD Millions), (2013-2015)
• Figure 6: Neuroendocrine Carcinoma US Market (USD Millions), (2016-2023)
• Figure 7: Neuroendocrine Carcinoma Germany Market (USD Millions), (2013-2015)
• Figure 8: Neuroendocrine Carcinoma Germany Market (USD Millions), (2016-2023)
• Figure 9: Neuroendocrine Carcinoma United Kingdom Market (USD Millions), (2013-2015)
• Figure 10: Neuroendocrine Carcinoma United Kingdom Market (USD Millions), (2016-2023)
• Figure 11: Neuroendocrine Carcinoma France Market (USD Millions), (2013-2015)
• Figure 12: Neuroendocrine Carcinoma France Market (USD Millions), (2016-2023)
• Figure 13: Neuroendocrine Carcinoma Italy Market (USD Millions), (2013-2015)
• Figure 14: Neuroendocrine Carcinoma Italy Market (USD Millions), (2016-2023)
• Figure 15: Neuroendocrine Carcinoma Spain Market (USD Millions), (2013-2015)
• Figure 16: Neuroendocrine Carcinoma Spain Market (USD Millions), (2016-2023)
• Figure 17: Neuroendocrine Carcinoma Japan Market (USD Millions), (2013-2015)
• Figure 18: Neuroendocrine Carcinoma Japan Market (USD Millions), (2015-2023)
• Figure 19: Neuroendocrine Carcinoma ROW Market (USD Millions), (2013-2015)
• Figure 20: Neuroendocrine Carcinoma ROW Market (USD Millions), (2016-2023)
• Novartis AG
• Pfizer Inc.
• Daiichi Sankyo Company Limited
• Celgene Corporation
• Bristol-Myers Squibb Company
• Barwon Health
• Assign Clinical Research GmbH
• Andarix Pharmaceuticals Inc.
• Advanced Accelerator Applications SA
• AbbVie Inc.
